Efficacy and safety of DL‐3‐n‐butylphthalide in patients with mild cognitive impairment: a multicentre, randomized, double‐blind, placebo‐controlled trial
Pin Wang, Wenxian Sun, Jin Gong, Xiaodong Han, Chang Xu, Yufei Chen, Yuting Yang, Heya Luan, Shaoqi Li, Ruina Li, Boye Wen, Sirong Lv, Cuibai Wei · 2025
Read Efficacy and safety of DL‐3‐n‐butylphthalide in patients with mild cognitive impairment: a multicentre, randomized, double‐blind, placebo‐controlled trial by Pin Wang, Wenxian Sun, Jin Gong, Xiaodong Han, Chang Xu, Yufei Chen, Yuting Yang, Heya Luan, Shaoqi Li, Ruina Li, Boye Wen, Sirong Lv, Cuibai Wei (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712863.txt.
Description
Pin Wang and co-authors report a 2025 clinical trial of a drug called DL-3-n-butylphthalide in people with mild cognitive impairment due to Alzheimer's disease. The drug, known as NBP, guards nerve cells in several ways and has already helped people with vessel-related thinking problems. Whether it helps in this disease was not known.
The trial ran for twelve months at several centres and enrolled 270 patients aged fifty to eighty-five. Half received the drug three times a day and half received a dummy capsule. The main test was change on a standard thinking scale, with safety checks throughout. Trials like this one decide whether the drug earns a place in care.
Catalog record
| CREATOR | Pin Wang, Wenxian Sun, Jin Gong, Xiaodong Han, Chang Xu, Yufei Chen, Yuting Yang, Heya Luan, Shaoqi Li, Ruina Li, Boye Wen, Sirong Lv, Cuibai Wei |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |